Kruskal–Wallis’s analysis showed that during the eGFR decline (p < 0.01 from median 23.5 mL/min), we observed an increase in MCP1 (p = 0.031 from median 470.4 pg/mL), iFGF23 (p-value <0.01 from median 91.5 pg/mL), and cFGF23 (p = 0.03 from median 140 RU/mL) from CKD stage 3 to stage 5. Here, CCL2 is linked to chronic kidney disease.